Abera Bioscience AB (NGM:ABERA)
Sweden
· Delayed Price · Currency is SEK 6.00
-0.10 (-1.64%)
At close: Mar 9, 2026
Abera Bioscience AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Other Revenue | 11.89 | 14.63 | 2.52 | 1.79 | 1.18 | Upgrade
|
| Revenue | 11.89 | 14.63 | 2.52 | 1.79 | 1.18 | Upgrade
|
| Revenue Growth (YoY) | -18.74% | 479.60% | 41.18% | 51.78% | 55.92% | Upgrade
|
| Gross Profit | 11.89 | 14.63 | 2.52 | 1.79 | 1.18 | Upgrade
|
| Selling, General & Admin | 22.12 | 15.72 | 19.35 | 21.19 | 10.34 | Upgrade
|
| Other Operating Expenses | 0.16 | 0.18 | 0.09 | 0.05 | 0.02 | Upgrade
|
| Operating Expenses | 22.47 | 15.97 | 19.45 | 21.24 | 10.35 | Upgrade
|
| Operating Income | -10.58 | -1.34 | -16.92 | -19.45 | -9.18 | Upgrade
|
| Interest Expense | - | -0 | - | - | -0 | Upgrade
|
| Interest & Investment Income | 0.13 | 0.02 | 0.08 | 0.01 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.22 | 0.12 | 0.06 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -0 | -0 | - | - | Upgrade
|
| Pretax Income | -10.45 | -1.1 | -16.72 | -19.38 | -9.17 | Upgrade
|
| Net Income | -10.45 | -1.1 | -16.72 | -19.38 | -9.17 | Upgrade
|
| Net Income to Common | -10.45 | -1.1 | -16.72 | -19.38 | -9.17 | Upgrade
|
| Shares Outstanding (Basic) | 17 | 16 | 13 | 12 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 16 | 13 | 12 | 10 | Upgrade
|
| Shares Change (YoY) | 5.59% | 18.42% | 13.66% | 14.64% | 45.39% | Upgrade
|
| EPS (Basic) | -0.63 | -0.07 | -1.26 | -1.66 | -0.90 | Upgrade
|
| EPS (Diluted) | -0.63 | -0.07 | -1.26 | -1.66 | -0.90 | Upgrade
|
| Free Cash Flow | -3.68 | -1.33 | -17.71 | -19.69 | -9.68 | Upgrade
|
| Free Cash Flow Per Share | -0.22 | -0.09 | -1.33 | -1.69 | -0.95 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -88.99% | -9.15% | -670.48% | -1088.19% | -779.01% | Upgrade
|
| Profit Margin | -87.94% | -7.52% | -662.44% | -1084.01% | -778.09% | Upgrade
|
| Free Cash Flow Margin | -30.99% | -9.09% | -701.70% | -1101.46% | -821.76% | Upgrade
|
| EBITDA | -10.39 | -1.28 | - | - | - | Upgrade
|
| EBITDA Margin | -87.38% | -8.73% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.19 | 0.06 | - | - | - | Upgrade
|
| EBIT | -10.58 | -1.34 | -16.92 | -19.45 | -9.18 | Upgrade
|
| EBIT Margin | -88.99% | -9.15% | - | - | - | Upgrade
|
| Revenue as Reported | 11.89 | 14.85 | 2.65 | 1.85 | 1.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.